COVID-19 中的过度炎症反应与免疫应答产生。
Hyperinflammation and Immune Response Generation in COVID-19.
机构信息
Defence Research and Development Organization (DRDO)-HQ, New Delhi, India.
National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India,
出版信息
Neuroimmunomodulation. 2020;27(2):80-86. doi: 10.1159/000513198. Epub 2020 Dec 18.
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) pandemic has affected millions of people worldwide. The pathophysiology of this virus is not very clearly known, thus, enormous efforts are being made by the scientific community to delineate its evading mechanism. In this review, we have summarized the hyperinflammation and humoral and cell-mediated immune response generated in human body after infection with the SARS-CoV-2 virus. The inflammatory response generated after infection by increased proinflammatory cytokines and chemokines, and complement proteins activation may likely contribute to disease severity. We also discussed the other factors that may affect immunity and could be important comorbidities in the disease severity and outcome.
摘要
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）可引起 2019 年冠状病毒病（COVID-19）大流行，已影响全球数百万人。该病毒的病理生理学尚不清楚，因此科学界正在做出巨大努力来阐明其逃避机制。在这篇综述中，我们总结了人体感染 SARS-CoV-2 病毒后产生的过度炎症反应以及体液和细胞介导的免疫反应。感染后产生的炎症反应可能与疾病的严重程度有关，其由促炎细胞因子和趋化因子增加以及补体蛋白激活引起。我们还讨论了可能影响免疫的其他因素，这些因素可能是疾病严重程度和结果的重要合并症。
相似文献
1
Hyperinflammation and Immune Response Generation in COVID-19.COVID-19 中的过度炎症反应与免疫应答产生。
Neuroimmunomodulation. 2020;27(2):80-86. doi: 10.1159/000513198. Epub 2020 Dec 18.
2
The Longitudinal Immune Response to Coronavirus Disease 2019: Chasing the Cytokine Storm.《2019 年冠状病毒病的纵向免疫反应：追寻细胞因子风暴》。
Arthritis Rheumatol. 2021 Jan;73(1):23-35. doi: 10.1002/art.41526. Epub 2020 Dec 1.
3
The immune response to SARS-CoV-2 and COVID-19 immunopathology - Current perspectives.SARS-CoV-2 与 COVID-19 免疫病理的免疫反应——当前观点。
Pulmonology. 2021 Sep-Oct;27(5):423-437. doi: 10.1016/j.pulmoe.2021.03.008. Epub 2021 Apr 9.
4
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
5
Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword.细胞因子风暴与 COVID-19：一把双刃剑。
Front Immunol. 2021 Sep 30;12:742941. doi: 10.3389/fimmu.2021.742941. eCollection 2021.
6
Innate and adaptive immune responses to SARS-CoV-2 in humans: relevance to acquired immunity and vaccine responses.人类对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的先天性和适应性免疫反应：与获得性免疫和疫苗反应的相关性
Clin Exp Immunol. 2021 Jun;204(3):310-320. doi: 10.1111/cei.13582. Epub 2021 Mar 4.
7
Impaired Cellular Immunity to SARS-CoV-2 in Severe COVID-19 Patients.严重 COVID-19 患者对 SARS-CoV-2 的细胞免疫受损。
Front Immunol. 2021 Feb 2;12:603563. doi: 10.3389/fimmu.2021.603563. eCollection 2021.
8
Robust and Functional Immune Memory Up to 9 Months After SARS-CoV-2 Infection: A Southeast Asian Longitudinal Cohort.SARS-CoV-2 感染后长达 9 个月的稳健且具有功能性的免疫记忆：一项东南亚纵向队列研究。
Front Immunol. 2022 Feb 3;13:817905. doi: 10.3389/fimmu.2022.817905. eCollection 2022.
9
Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic.针对 COVID-19 大流行，对癌症患者的细胞免疫组进行研究。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-002087.
10
Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents.评估 SARS-CoV-2 免疫在康复期儿童和青少年中的作用。
Front Immunol. 2021 Dec 17;12:797919. doi: 10.3389/fimmu.2021.797919. eCollection 2021.
引用本文的文献
1
Management of Severe SARS-CoV-2-Associated Organizing Pneumonia With Immunoglobulins.使用免疫球蛋白治疗严重的新型冠状病毒2型相关机化性肺炎
Cureus. 2025 Jan 8;17(1):e77120. doi: 10.7759/cureus.77120. eCollection 2025 Jan.
2
An interferon-stimulated long non-coding RNA USP30-AS1 as an immune modulator in influenza A virus infection.一种干扰素刺激的长链非编码RNA USP30-AS1作为甲型流感病毒感染中的免疫调节剂。
PLoS Pathog. 2025 Jan 8;21(1):e1012854. doi: 10.1371/journal.ppat.1012854. eCollection 2025 Jan.
3
COVID-19: a multi-organ perspective.新型冠状病毒肺炎：多器官视角。
Front Cell Infect Microbiol. 2024 Oct 18;14:1425547. doi: 10.3389/fcimb.2024.1425547. eCollection 2024.
4
A Retrospective Study: Evaluating the Impact of the COVID-19 Pandemic on Inflammatory Markers in Hospitalized Patients.一项回顾性研究：评估新冠疫情对住院患者炎症标志物的影响
Infect Dis Rep. 2024 Aug 14;16(4):735-749. doi: 10.3390/idr16040056.
5
In Silico and In Vitro Evaluation of the Molecular Mimicry of the SARS-CoV-2 Spike Protein by Common Short Constituent Sequences (cSCSs) in the Human Proteome: Toward Safer Epitope Design for Vaccine Development.人蛋白质组中常见短组成序列（cSCSs）对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白分子模拟的计算机模拟和体外评估：迈向更安全的疫苗开发表位设计
Vaccines (Basel). 2024 May 14;12(5):539. doi: 10.3390/vaccines12050539.
6
HMGB1 mediates microbiome-immune axis dysregulation underlying reduced neutralization capacity in obesity-related post-acute sequelae of SARS-CoV-2.高迁移率族蛋白 B1 介导了微生物组-免疫轴的失调，导致肥胖相关的 SARS-CoV-2 急性后遗症中和能力降低。
Sci Rep. 2024 Jan 3;14(1):355. doi: 10.1038/s41598-023-50027-1.
7
Repositioned Natural Compounds and Nanoformulations: A Promising Combination to Counteract Cell Damage and Inflammation in Respiratory Viral Infections.重定位天然化合物和纳米制剂：一种有前途的组合，可抵抗呼吸道病毒感染中的细胞损伤和炎症。
Molecules. 2023 May 12;28(10):4045. doi: 10.3390/molecules28104045.
8
Chronic Comorbidities in Middle Aged Patients Contribute to Ineffective Emergency Hematopoiesis in Covid-19 Fatal Outcomes.中老年患者的慢性共病导致新冠病毒感染死亡结局中应急造血无效。
Arch Med Res. 2023 Apr;54(3):197-210. doi: 10.1016/j.arcmed.2023.03.003. Epub 2023 Mar 15.
9
Immune cell landscape in symptomatic and asymptomatic SARS-CoV-2 infected adults and children in urban Dhaka, Bangladesh.孟加拉国达卡市有症状和无症状的 SARS-CoV-2 感染成年和儿童的免疫细胞图谱。
Immunobiology. 2023 Mar;228(2):152350. doi: 10.1016/j.imbio.2023.152350. Epub 2023 Feb 18.
10
Management of hyperinflammation in COVID-19 patients.COVID-19 患者的过度炎症反应管理。
Rev Esp Quimioter. 2022 Oct;35 Suppl 3(Suppl 3):6-9. doi: 10.37201/req/s03.02.2022. Epub 2022 Oct 24.
本文引用的文献
1
Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation.高致病性冠状病毒 N 蛋白通过 MASP-2 介导的凝集素补体途径过度激活加重炎症。
Signal Transduct Target Ther. 2022 Sep 14;7(1):318. doi: 10.1038/s41392-022-01133-5.
2
Reduced numbers of T cells and B cells correlates with persistent SARS-CoV-2 presence in non-severe COVID-19 patients.T 细胞和 B 细胞数量减少与非重症 COVID-19 患者中持续存在 SARS-CoV-2 相关。
Sci Rep. 2020 Oct 19;10(1):17718. doi: 10.1038/s41598-020-73955-8.
3
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.I 型干扰素易感性区分 SARS-CoV-2 和 SARS-CoV。
J Virol. 2020 Nov 9;94(23). doi: 10.1128/JVI.01410-20.
4
Definition and Risks of Cytokine Release Syndrome in 11 Critically Ill COVID-19 Patients With Pneumonia: Analysis of Disease Characteristics.新冠肺炎肺炎 11 例危重症患者细胞因子释放综合征的定义和风险：疾病特征分析。
J Infect Dis. 2020 Oct 1;222(9):1444-1451. doi: 10.1093/infdis/jiaa387.
5
A single-cell atlas of the peripheral immune response in patients with severe COVID-19.严重 COVID-19 患者外周免疫反应的单细胞图谱。
Nat Med. 2020 Jul;26(7):1070-1076. doi: 10.1038/s41591-020-0944-y. Epub 2020 Jun 8.
6
Human neutralizing antibodies elicited by SARS-CoV-2 infection.SARS-CoV-2 感染诱导的人体中和抗体。
Nature. 2020 Aug;584(7819):115-119. doi: 10.1038/s41586-020-2380-z. Epub 2020 May 26.
7
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals.新型冠状病毒感染恢复期个体中 SARS-CoV-2 特异性体液和细胞免疫的检测。
Immunity. 2020 Jun 16;52(6):971-977.e3. doi: 10.1016/j.immuni.2020.04.023. Epub 2020 May 3.
8
Herd immunity and COVID-19.群体免疫与新冠病毒病
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4064-4065. doi: 10.26355/eurrev_202004_20978.
9
SARS-CoV-2 variants: Relevance for symptom granularity, epidemiology, immunity (herd, vaccines), virus origin and containment?SARS-CoV-2 变体：与症状细微差别、流行病学、免疫（群体、疫苗）、病毒起源和控制的相关性？
Environ Microbiol. 2020 Jun;22(6):2001-2006. doi: 10.1111/1462-2920.15053. Epub 2020 May 19.
10
Antiviral activities of type I interferons to SARS-CoV-2 infection.I 型干扰素对 SARS-CoV-2 感染的抗病毒活性。
Antiviral Res. 2020 Jul;179:104811. doi: 10.1016/j.antiviral.2020.104811. Epub 2020 Apr 29.
Zotero 插件